CELLIVERY THERAPEUTICS INC has a total of 41 patent applications. It decreased the IP activity by 28.0%. Its first patent ever was published in 2015. It filed its patents most often in United States, EPO (European Patent Office) and WIPO (World Intellectual Property Organization). Its main competitors in its focus markets biotechnology, pharmaceuticals and measurement are JO DAEWOONG, I2 PHARMACEUTICALS INC and INT GENETIC ENG.
# | Country | Total Patents | |
---|---|---|---|
#1 | United States | 15 | |
#2 | EPO (European Patent Office) | 10 | |
#3 | WIPO (World Intellectual Property Organization) | 7 | |
#4 | Republic of Korea | 3 | |
#5 | Australia | 2 | |
#6 | Canada | 2 | |
#7 | China | 2 |
# | Industry | |
---|---|---|
#1 | Biotechnology | |
#2 | Pharmaceuticals | |
#3 | Measurement | |
#4 | Foods and drinks |
# | Technology | |
---|---|---|
#1 | Peptides | |
#2 | Medical preparations | |
#3 | Analysing materials | |
#4 | Microorganisms | |
#5 | Therapeutic chemical compounds | |
#6 | Enzymes |
# | Name | Total Patents |
---|---|---|
#1 | Jo Daewoong | 41 |
#2 | Lee Kuysook | 5 |
#3 | Choi Youngsil | 5 |
#4 | Shin Seulmee | 4 |
#5 | Kim Jeongmin | 2 |
#6 | Kim Jihye | 2 |
#7 | Lee Soyeong | 2 |
#8 | Kim Chohyun | 2 |
#9 | Jang Junho | 1 |
#10 | Hwang Younseo | 1 |
Publication | Filing date | Title |
---|---|---|
US2019233835A1 | Cell-permeable (cp)-cas9 recombinant protein and uses thereof | |
EP3337815A1 | Cell-permeable (cp)- socs3 recombinant protein and uses thereof | |
EP3334756A1 | Improved cell-permeable cre (icp-cre) recombinant protein and use thereof | |
EP3334755A1 | Improved cell-permeable reprogramming factor (icp-rf) recombinant protein and use thereof | |
US2017240598A1 | Advanced macromolecule transduction domain (aMTD) sequences for improvement of cell-permeability, polynucleotides encoding the same, method to identify the unique features of aMTDs comprising the same, method to develop the aMTD sequences comprising the same |